肺炎克雷伯菌
内科学
肺炎
痰
风险因素
医院获得性肺炎
碳青霉烯
磺胺甲恶唑
甲氧苄啶
流行病学
医学
感染控制
回顾性队列研究
微生物学
生物
重症监护医学
抗生素
肺结核
病理
生物化学
大肠杆菌
基因
作者
Yan Zuo,Dongmei Zhao,Guobin Song,Jiabin Li,Yuanhong Xu,Zhongxin Wang
标识
DOI:10.1089/mdr.2020.0162
摘要
This study was conducted to acknowledge microbiological and clinical characteristics of hospital-acquired pneumonia (HAP) caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). A retrospective, 1:1 matched (age, gender, specimen source, and ward) case-control study was conducted during 2015–2017 in a tertiary teaching hospital in Anhui, China. Multivariate logistic regression analysis demonstrated that prior central venous catheter use, sputum suction, continuous renal replacement therapy, and exposure to fluroquinolones were independent risk factors for the morbidity of CRKP infection for HAP. Treatment failure for infection was an independent risk factor for crude in-hospital mortality, while the use of fluroquinolones may improve the effective treatment for infection (p = 0.040). Among 74 CRKP strains, 85.1% of them were positive for the production of KPC-2, and one of them was detected for co-harboring blaKPC-2 and blaIMP-38-like. Separately, sequence type (ST) 11 (81.1%) was the predominant ST in this study, and ST11 CRKP isolates were related with higher detection rate of blaKPC-2 and lower resistance rate to trimethoprim/sulfamethoxazole when compared with non-ST11 ones. Moreover, resistance to carbapenem was associated with higher mortality (35.1%) and hospitalization costs for HAP patients with K. pneumoniae infection. Invasive procedures may increase the morbidity of CRKP infection for HAP. Prior exposure to fluroquinolones is associated with the development of resistance, but as a targeted treatment it may be effective.
科研通智能强力驱动
Strongly Powered by AbleSci AI